Showing 2801-2810 of 3315 results for "".
- Reed Exhibitions Unveils New Brand Identityhttps://modernod.com/news/reed-exhibitions-unveils-new-brand-identity/2479287/Reed Exhibitions announced its evolution to RX, with a refreshed visual identity and updated brand positioning, according to The Vision Council. Building on its flagship events business, the company is leveraging its capabilities in data and technology to create
- Oyster Point Pharma Announces Collaboration with Adaptive Phage Therapeutics to Target Ophthalmic Diseaseshttps://modernod.com/news/oyster-point-pharma-announces-collaboration-with-adaptive-phage-therapeutics-to-target-ophthalmic-diseases/2479281/Oyster Point Pharma announced a newly formed research collaboration with Adaptive Phage Therapeutics (APT) to leverage APT’s PhageBank technology for the development of potential treatments for multiple ophthalmic diseases. APT’s PhageBank technology is engi
- J&J Vision Launches Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System in Europehttps://modernod.com/news/jj-vision-announces-launch-of-tecnis-eyhance-toric-ii-iol-with-tecnis-simplicity-delivery-system-in-europe/2479274/Johnson & Johnson Vision announced the launch and availability of its Tecnis Eyhance Toric II IOL with Tecnis Simplicity Delivery System for the treatment of cataracts patients with astigmatism in Europe. This monofocal lens allows for high-quality vision at both intermediate and far distance
- Oxular Appoints Dr. Friedrich Asmus as Chief Medical Officerhttps://modernod.com/news/oxular-appoints-dr-friedrich-asmus-as-chief-medical-officer/2479267/Oxular Limited announced it has appointed Friedrich (Fritz) Asmus, MD, as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the company’s lead asset, OXU‑001, for the treatment of diabetic macular edema (DME), and to accelerate the development o
- High Caffeine Consumption May Be Associated With Increased Risk of Glaucomahttps://modernod.com/news/high-caffeine-consumption-may-be-associated-with-increased-risk-of-blinding-eye-disease/2479268/Consuming large amounts of daily caffeine may increase the risk of glaucoma more than three-fold for those with a genetic predisposition to higher eye pressure, according to an international multicenter study. The research led by the Icahn School of Medicine at Mount Sinai is the first to demonst
- Kala Pharmaceuticals Announces Eysuvis Now Covered by OptumRxhttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-optumrx/2479263/Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. “We are pleased to announce
- VSY Biotechnology Announces Launch of the Enova C Haptic Model IOLhttps://modernod.com/news/vsy-biotechnology-announces-launch-of-the-enova-c-haptic-model-iol/2479260/VSY Biotechnology announced the launch of the Enova C Haptic Model IOL. Enova is the first and only 100% glistening-free, dry-packed hydrophobic acrylic IOL, according to VSY Biotechnology. The lens requires no warming or special conditioning before surgery. The composition of Enova mater
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa
- Neurophth Therapeutics and Hopstem Biotechnology Partner to Develop Human Induced Pluripotent Stem Cell-Derived Therapies for Ocular Diseaseshttps://modernod.com/news/neurophth-therapeutics-and-hopstem-biotechnology-partner-to-develop-human-induced-pluripotent-stem-cell-derived-therapies-for-ocular-diseases/2479248/Neurophth Biotechnology and Hopstem Biotechnology announced a strategic partnership aiming to provide human iPSC-derived cell therapy for ocular diseases. The partnership leverages Neurophth’s experience in global gene/cell therapy drugs development and understanding of ophthalmic di
- GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of Lumevoq Versus Natural Historyhttps://modernod.com/news/gensight-biologics-announces-publication-of-indirect-comparison-showing-treatment-effect-of-lumevoq-versus-natural-history/2479249/GenSight Biologics announced that the journal Frontiers in Neurology has published results of the indirect comparison of the evolution of visual outcomes in patients treated with Lumevoq gene therapy with the spontaneous evolution in natural history (NH) studies of Leber hereditary optic